Paclitaxel is incorporated by mesenchymal stromal cells and released in exosomes that inhibit in vitro tumor growth: a new approach for drug delivery.

By L. Pascucci, V. Coccè, A. Bonomi, Diletta Ami, P. Ceccarelli, E. Ciusani, L. Viganò, A. Locatelli, F. Sisto, S. Doglia and 6 more. Journal of Controlled Release, 2014

818 citations recorded by the source corpus.

Subfields: Cancer Research, Genetics, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/95f6b21a9997b53301c9dd770c02fb4d939c105b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. Yan Luo
2. Ben Wang
3. Chuanjiang He
4. Shu Zheng
5. P. Vader
6. Jan Lötvall
7. Edit I. Buzás
8. Ramesh C. Gupta

In Genetics

1. Lorraine O'Driscoll
2. P. Vader
3. B. W. van Balkom

In Molecular Biology

1. C. Théry
2. P. Vader
3. Yan Luo
4. Ben Wang
5. Chuanjiang He
6. Shu Zheng
7. Jan Lötvall
8. Edit I. Buzás

Citations in the corpus

• Development of Exosome-encapsulated Paclitaxel to Overcome MDR in Cancer cells (2015, neutral): “The same effect was reported with PTX in Pgp-overexpressing bone marrow mesenchymal stromal cells (SR4987) (45).”
• Applying extracellular vesicles based therapeutics in clinical trials – an ISEV position paper (2015, background): “PTX-loaded EVs, released from PTX-treated MSCs in vitro, have been shown to inhibit the proliferation of cultured tumour cells (240).”
• Exosome: A Review of Its Classification, Isolation Techniques, Storage, Diagnostic and Targeted Therapy Applications (2020, neutral): “23 In addition, MSC exosomes have been shown to play a role in the development of many diseases.”
• Exosome Theranostics: Biology and Translational Medicine (2018, background): “In addition, other therapeutic compounds, such as paclitaxel [172] and doxorubicin [173], can be packaged into exosomes for crossing the blood-brain barrier and achieving targeted delivery.”